Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Eur J Pharmacol ; 910: 174483, 2021 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-34481878

RESUMEN

The concept of "Neurovascular Unit" (NVU) was put forward, so that the research goal of Central Nervous System (CNS) diseases gradually transitioned from a single neuron to the structural and functional integrity of the NVU. Zebrafish has the advantages of high homology with human genes, strong reproductive capacity and visualization of neural circuits, so it has become an emerging model organism for NVU research and has been applied to a variety of CNS diseases. Based on CNKI (https://www.cnki.net/) and PubMed (https://pubmed.ncbi.nlm.nih.gov/about/) databases, the author of this article sorted out the relevant literature, analyzed the construction of a zebrafish model of various CNS diseases,and the use of diagrams showed the application of zebrafish in the NVU, revealed its relationship, which would provide new methods and references for the treatment and research of CNS diseases.


Asunto(s)
Fármacos del Sistema Nervioso Central/farmacología , Enfermedades del Sistema Nervioso Central/fisiopatología , Sistema Nervioso Central/fisiología , Acoplamiento Neurovascular/fisiología , Pez Cebra/fisiología , Animales , Barrera Hematoencefálica/citología , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/fisiología , Sistema Nervioso Central/irrigación sanguínea , Sistema Nervioso Central/efectos de los fármacos , Fármacos del Sistema Nervioso Central/uso terapéutico , Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Modelos Animales de Enfermedad , Humanos , Microglía/efectos de los fármacos , Microglía/fisiología , Modelos Animales , Neuronas/efectos de los fármacos , Neuronas/fisiología , Acoplamiento Neurovascular/efectos de los fármacos
2.
Int J Mol Sci ; 22(3)2021 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-33573189

RESUMEN

Hyperglycemia alters the function of cerebral endothelial cells from the blood-brain barrier, increasing the risk of cerebrovascular complications during diabetes. This study evaluated the protective effect of polyphenols on inflammatory and permeability markers on bEnd3 cerebral endothelial cells exposed to high glucose concentration. Results show that hyperglycemic condition increased nuclear factor kappa B (NFκB) activity, deregulated the expression of interleukin-1 beta (IL-1ß), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-10 (IL-10) and endothelial-leukocyte adhesion molecule (E-selectin) genes, raised MCP-1 secretion and elevated monocyte adhesion and transendothelial migration. High glucose decreased occludin, claudin-5, zona occludens-1 (ZO-1) and zona occludens-2 (ZO-2) tight junctions production and altered the endothelial permeability. Characterized polyphenolic extracts from the French medicinal plants Antirhea borbonica, Ayapana triplinervis, Dodonaea viscosa and Terminalia bentzoe, and their major polyphenols quercetin, caffeic, chlorogenic and gallic acids limited the pro-inflammatory and permeability alterations caused by high glucose. Peroxisome proliferator-activated receptor gamma (PPARγ) agonist also attenuated these damages while PPARγ antagonist aggravated them, suggesting PPARγ protective action. Interestingly, polyphenols improved PPARγ gene expression lowered by high glucose. Moreover, polyphenols were detected at the intracellular level or membrane-bound to cells, with evidence for breast cancer resistance protein (BCRP) efflux transporter role. Altogether, these findings emphasize the ability of polyphenols to protect cerebral endothelial cells in hyperglycemic condition and their relevance for pharmacological strategies aiming to limit cerebrovascular disorders in diabetes.


Asunto(s)
Barrera Hematoencefálica/efectos de los fármacos , Trastornos Cerebrovasculares/prevención & control , Hiperglucemia/inmunología , Extractos Vegetales/farmacología , Polifenoles/farmacología , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/metabolismo , Animales , Glucemia/metabolismo , Barrera Hematoencefálica/citología , Barrera Hematoencefálica/inmunología , Barrera Hematoencefálica/patología , Permeabilidad Capilar/efectos de los fármacos , Permeabilidad Capilar/inmunología , Línea Celular , Trastornos Cerebrovasculares/etiología , Trastornos Cerebrovasculares/inmunología , Trastornos Cerebrovasculares/patología , Evaluación Preclínica de Medicamentos , Células Endoteliales/inmunología , Células Endoteliales/patología , Endotelio Vascular/citología , Endotelio Vascular/inmunología , Endotelio Vascular/patología , Humanos , Hiperglucemia/sangre , Hiperglucemia/complicaciones , Ratones , Monocitos/efectos de los fármacos , Monocitos/inmunología , FN-kappa B/metabolismo , PPAR gamma/agonistas , PPAR gamma/antagonistas & inhibidores , PPAR gamma/metabolismo , Extractos Vegetales/uso terapéutico , Polifenoles/uso terapéutico , Transducción de Señal/efectos de los fármacos , Uniones Estrechas/efectos de los fármacos , Uniones Estrechas/inmunología , Uniones Estrechas/patología
3.
J Vis Exp ; (165)2020 11 19.
Artículo en Inglés | MEDLINE | ID: mdl-33283783

RESUMEN

Brain microvascular endothelial cells (BMECs) can be differentiated from human induced pluripotent stem cells (iPSCs) to develop ex vivo cellular models for studying blood-brain barrier (BBB) function. This modified protocol provides detailed steps to derive, expand, and cryopreserve BMECs from human iPSCs using a different donor and reagents than those reported in previous protocols. iPSCs are treated with essential 6 medium for 4 days, followed by 2 days of human endothelial serum-free culture medium supplemented with basic fibroblast growth factor, retinoic acid, and B27 supplement. At day 6, cells are sub-cultured onto a collagen/fibronectin matrix for 2 days. Immunocytochemistry is performed at day 8 for BMEC marker analysis using CLDN5, OCLN, TJP1, PECAM1, and SLC2A1. Western blotting is performed to confirm BMEC marker expression, and absence of SOX17, an endodermal marker. Angiogenic potential is demonstrated with a sprouting assay. Trans-endothelial electrical resistance (TEER) is measured using chopstick electrodes and voltohmmeter starting at day 7. Efflux transporter activity for ATP binding cassette subfamily B member 1 and ATP binding cassette subfamily C member 1 is measured using a multi-plate reader at day 8. Successful derivation of BMECs is confirmed by the presence of relevant cell markers, low levels of SOX17, angiogenic potential, transporter activity, and TEER values ~2000 Ω x cm2. BMECs are expanded until day 10 before passaging onto freshly coated collagen/fibronectin plates or cryopreserved. This protocol demonstrates that iPSC-derived BMECs can be expanded and passaged at least once. However, lower TEER values and poorer localization of BMEC markers was observed after cryopreservation. BMECs can be utilized in co-culture experiments with other cell types (neurons, glia, pericytes), in three-dimensional brain models (organ-chip and hydrogel), for vascularization of brain organoids, and for studying BBB dysfunction in neuropsychiatric disorders.


Asunto(s)
Encéfalo/irrigación sanguínea , Encéfalo/citología , Criopreservación , Células Endoteliales/citología , Células Madre Pluripotentes Inducidas/citología , Membrana Basal/efectos de los fármacos , Membrana Basal/metabolismo , Biomarcadores/metabolismo , Barrera Hematoencefálica/citología , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Técnicas de Cocultivo , Colágeno Tipo IV/farmacología , Impedancia Eléctrica , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Matriz Extracelular/efectos de los fármacos , Matriz Extracelular/metabolismo , Fibronectinas/farmacología , Humanos , Células Madre Pluripotentes Inducidas/efectos de los fármacos , Células Madre Pluripotentes Inducidas/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Neovascularización Fisiológica/efectos de los fármacos
4.
J Ethnopharmacol ; 247: 112253, 2020 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-31562952

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: The medicinal properties of grapes (Vitis vinifera L.) are well known since ancient times. Ethnobotanical grape preparations, like the Ayurvedic Darakchasava are used as cardiotonic and for the treatment of cardiovascular diseases. Dried grape products are also applied in Iranian traditional medicine for memory problems, which are linked to the pathology of brain microvessels, a special part of the cardiovascular system. The anti-inflammatory and protective effects of these traditional preparations on the cardiovascular system are related to their bioactive phenolic compounds. AIM OF THE STUDY: The blood-brain barrier (BBB), formed by brain capillaries, is not only involved in inflammatory and other diseases of the central nervous system, but also in many systemic diseases with an inflammatory component. Dietary obesity is a systemic chronic inflammatory condition in which the peripheral and central vascular system is affected. Among the cerebrovascular changes in obesity defective leptin transport across the BBB related to central leptin resistance is observed. Our aim was to study the protective effects of grape phenolic compounds epicatechin (EC), gallic acid (GA) and resveratrol (RSV) and grape-seed proanthocyanidin-rich extract (GSPE) on a cytokine-induced vascular endothelial inflammation model. Using a culture model of the BBB we investigated cytokine-induced endothelial damage and changes in the expression of leptin receptors and leptin transfer. MATERIALS AND METHODS: For the BBB model, primary cultures of rat brain endothelial cells, glial cells and pericytes were used in co-culture. Cells were treated by tumor necrosis factor-α (TNF-α) and interleukin-1 ß (IL-1ß) (10 ng/ml each) to induce damage. Cell toxicity was evaluated by the measurement of impedance. The expression of leptin receptors was assessed by RT-qPCR and western blot. The production of reactive oxygen species (ROS) and nitric oxide (NO) were detected by fluorescent probes. RESULTS: GSPE (10 µg/ml), EC (10 µM), GA (1 µM) or RSV (10 µM) did not change the viability of brain endothelial cells. The gene expression of the short leptin receptor isoform, Ob-Ra, was up-regulated by GSPE, EC and RSV, while the mRNA levels of Lrp2 and clusterin, clu/ApoJ were not affected. The tested compounds did not change the expression of the long leptin receptor isoform, Ob-Rb. RSV protected against the cytokine-induced increase in albumin permeability of the BBB model. GSPE and EC exerted an antioxidant effect and GSPE increased NO both alone and in the presence of cytokines. The cytokine-induced nuclear translocation of transcription factor NF-κB was blocked by GSPE, GA and RSV. Cytokines increased the mRNA expression of Lrp2 which was inhibited by EC. RSV increased Ob-Ra and Clu in the presence of cytokines. Cytokines elevated leptin transfer across the BBB model, which was not modified by GSPE or RSV. CONCLUSION: Our results obtained on cell culture models confirm that natural grape compounds protect vascular endothelial cells against inflammatory damage in accordance with the ethnopharmacological use of grape preparations in cardiovascular diseases. Furthermore, grape compounds and GSPE, by exerting a beneficial effect on the BBB, may also be considered in the treatment of obesity after validation in clinical trials.


Asunto(s)
Barrera Hematoencefálica/efectos de los fármacos , Células Endoteliales/efectos de los fármacos , Extracto de Semillas de Uva/farmacología , Inflamación/tratamiento farmacológico , Proantocianidinas/farmacología , Vitis/química , Animales , Animales Recién Nacidos , Astrocitos , Barrera Hematoencefálica/citología , Barrera Hematoencefálica/inmunología , Catequina/farmacología , Células Cultivadas , Citocinas/inmunología , Evaluación Preclínica de Medicamentos , Células Endoteliales/inmunología , Células Endoteliales/patología , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/inmunología , Etnofarmacología , Ácido Gálico/farmacología , Extracto de Semillas de Uva/química , Extracto de Semillas de Uva/uso terapéutico , Humanos , Inflamación/inmunología , Inflamación/patología , Leptina/inmunología , Leptina/metabolismo , Medicina Ayurvédica/métodos , Cultivo Primario de Células , Proantocianidinas/química , Proantocianidinas/uso terapéutico , Ratas , Especies Reactivas de Oxígeno/metabolismo , Receptores de Leptina/metabolismo , Resveratrol/farmacología
5.
J Pharm Biomed Anal ; 177: 112885, 2020 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-31563759

RESUMEN

Tianma pills, a traditional formula made from Ligusticum chuanxiong and Gastrodia elata, are efficacious for the treatment of primary headache. Tetramethylpyrazine (TMP) and Ferulic acid (FA) are the bioactive ingredients of Ligusticum chuanxiong, while Gastrodin and Gastrodigenin are the bioactive ingredients of Gastrodia elata. Pharmacokinetic assessment of TMP, FA, gastrodin or gastrodigenin in blood or brain interstitial fluid (BIF) has been reported in healthy animals. However, the pharmacokinetic properties of TMP and FA have not been studied when they are co-administered in a blood-stasis migraine model. The present research investigated the pharmacokinetic behavior of TMP and FA after oral administration in the presence of different concentrations of gastrodin and gastrodigenin in a blood-stasis migraine model. Pharmacokinetic parameters were determined using blood-brain microdialysis in combination with the UHPLC-MS method. Compared to the control group, in which TMP and FA were administrated without gastrodin or gastrodigenin, the T1/2, MRT, Cmax and AUC0-∞ of TMP and FA were increased. These results indicate that varying concentrations of gastrodin and gastrodigenin play an important role in affecting the pharmacokinetics of TMP and FA. Low concentrations of gastrodin and gastrodigenin (similar to those found in Tianma pills) were more efficacious, validating the utility of the ancient formulation.


Asunto(s)
Barrera Hematoencefálica/metabolismo , Medicamentos Herbarios Chinos/farmacocinética , Gastrodia/química , Ligusticum/química , Trastornos Migrañosos/tratamiento farmacológico , Administración Oral , Animales , Alcoholes Bencílicos/administración & dosificación , Alcoholes Bencílicos/farmacocinética , Barrera Hematoencefálica/química , Barrera Hematoencefálica/citología , Frío/efectos adversos , Ácidos Cumáricos/administración & dosificación , Ácidos Cumáricos/farmacocinética , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/química , Líquido Extracelular/química , Glucósidos/administración & dosificación , Glucósidos/farmacocinética , Humanos , Masculino , Microdiálisis , Trastornos Migrañosos/sangre , Trastornos Migrañosos/etiología , Permeabilidad , Pirazinas/administración & dosificación , Pirazinas/farmacocinética , Ratas , Organismos Libres de Patógenos Específicos , Vasoconstricción/efectos de los fármacos
6.
Biotechnol Bioeng ; 117(4): 1127-1136, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31885078

RESUMEN

Disruption of the blood-brain barrier (BBB) leads to various neurovascular diseases. Development of therapeutics required to cross the BBB is difficult due to a lack of relevant in vitro models. We have developed a three-dimensional (3D) microfluidic BBB chip (BBBC) to study cell interactions in the brain microvasculature and to test drug candidates of neurovascular diseases. We isolated primary brain microvascular endothelial cells (ECs), pericytes, and astrocytes from neonatal rats and cocultured them in the BBBC. To mimic the 3D in vivo BBB structure, we used type I collagen hydrogel to pattern the microchannel via viscous finger patterning technique to create a matrix. ECs, astrocytes, and pericytes were cocultured in the collagen matrix. The fluid flow in the BBBC was controlled by a pump-free strategy utilizing gravity as driving force and resistance in a paper-based flow resistor. The primary cells cultured in the BBBC expressed high levels of junction proteins and formed a tight endothelial barrier layer. Addition of tumor necrosis factor alpha to recapitulate neuroinflammatory conditions compromised the BBB functionality. To mitigate the neuroinflammatory stimulus, we treated the BBB model with the glucocorticoid drug dexamethasone, and observed protection of the BBB. This BBBC represents a new simple, cost-effective, and scalable in vitro platform for validating therapeutic drugs targeting neuroinflammatory conditions.


Asunto(s)
Barrera Hematoencefálica , Técnicas de Cocultivo/instrumentación , Evaluación Preclínica de Medicamentos/instrumentación , Dispositivos Laboratorio en un Chip , Animales , Antiinflamatorios/farmacología , Astrocitos/citología , Astrocitos/efectos de los fármacos , Astrocitos/metabolismo , Barrera Hematoencefálica/citología , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/metabolismo , Encéfalo/citología , Células Cultivadas , Técnicas de Cocultivo/métodos , Diseño de Equipo , Inflamación/metabolismo , Técnicas Analíticas Microfluídicas/instrumentación , Pericitos/citología , Pericitos/efectos de los fármacos , Pericitos/metabolismo , Ratas , Ratas Sprague-Dawley
7.
Stem Cell Reports ; 12(6): 1380-1388, 2019 06 11.
Artículo en Inglés | MEDLINE | ID: mdl-31189096

RESUMEN

Human induced pluripotent stem cell (iPSC)-derived developmental lineages are key tools for in vitro mechanistic interrogations, drug discovery, and disease modeling. iPSCs have previously been differentiated to endothelial cells with blood-brain barrier (BBB) properties, as defined by high transendothelial electrical resistance (TEER), low passive permeability, and active transporter functions. Typical protocols use undefined components, which impart unacceptable variability on the differentiation process. We demonstrate that replacement of serum with fully defined components, from common medium supplements to a simple mixture of insulin, transferrin, and selenium, yields BBB endothelium with TEER in the range of 2,000-8,000 Ω × cm2 across multiple iPSC lines, with appropriate marker expression and active transporters. The use of a fully defined medium vastly improves the consistency of differentiation, and co-culture of BBB endothelium with iPSC-derived astrocytes produces a robust in vitro neurovascular model. This defined differentiation scheme should broadly enable the use of human BBB endothelium for diverse applications.


Asunto(s)
Barrera Hematoencefálica/metabolismo , Técnicas de Cultivo de Célula , Diferenciación Celular , Células Endoteliales/metabolismo , Células Madre Pluripotentes Inducidas/metabolismo , Barrera Hematoencefálica/citología , Medios de Cultivo , Células Endoteliales/citología , Humanos , Células Madre Pluripotentes Inducidas/citología
8.
Nat Commun ; 10(1): 2621, 2019 06 13.
Artículo en Inglés | MEDLINE | ID: mdl-31197168

RESUMEN

The high selectivity of the human blood-brain barrier (BBB) restricts delivery of many pharmaceuticals and therapeutic antibodies to the central nervous system. Here, we describe an in vitro microfluidic organ-on-a-chip BBB model lined by induced pluripotent stem cell-derived human brain microvascular endothelium interfaced with primary human brain astrocytes and pericytes that recapitulates the high level of barrier function of the in vivo human BBB for at least one week in culture. The endothelium expresses high levels of tight junction proteins and functional efflux pumps, and it displays selective transcytosis of peptides and antibodies previously observed in vivo. Increased barrier functionality was accomplished using a developmentally-inspired induction protocol that includes a period of differentiation under hypoxic conditions. This enhanced BBB Chip may therefore represent a new in vitro tool for development and validation of delivery systems that transport drugs and therapeutic antibodies across the human BBB.


Asunto(s)
Barrera Hematoencefálica/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Células Endoteliales/metabolismo , Microfluídica/instrumentación , Anticuerpos/farmacología , Astrocitos , Barrera Hematoencefálica/citología , Evaluación Preclínica de Medicamentos/instrumentación , Evaluación Preclínica de Medicamentos/métodos , Endotelio Vascular/citología , Humanos , Dispositivos Laboratorio en un Chip , Microfluídica/métodos , Microvasos/citología , Pericitos , Permeabilidad , Células Madre Pluripotentes , Cultivo Primario de Células/instrumentación , Cultivo Primario de Células/métodos
9.
Cell Rep ; 19(11): 2257-2271, 2017 06 13.
Artículo en Inglés | MEDLINE | ID: mdl-28614713

RESUMEN

Neurons expressing agouti-related protein (AgRP) are essential for feeding. The majority of these neurons are located outside the blood-brain barrier (BBB), allowing them to directly sense circulating metabolic factors. Here, we show that, in adult mice, AgRP neurons outside the BBB (AgRPOBBB) were rapidly ablated by peripheral administration of monosodium glutamate (MSG), whereas AgRP neurons inside the BBB and most proopiomelanocortin (POMC) neurons were spared. MSG treatment induced proliferation of tanycytes, the putative hypothalamic neural progenitor cells, but the newly proliferated tanycytes did not become neurons. Intriguingly, AgRPOBBB neuronal number increased within a week after MSG treatment, and newly emerging AgRP neurons were derived from post-mitotic cells, including some from the Pomc-expressing cell lineage. Our study reveals that the lack of protection by the BBB renders AgRPOBBB vulnerable to lesioning by circulating toxins but that the rapid re-emergence of AgRPOBBB is part of a reparative process to maintain energy balance.


Asunto(s)
Barrera Hematoencefálica/citología , Hipotálamo/citología , Neuronas/citología , Proopiomelanocortina/metabolismo , Animales , Transporte Biológico , Barrera Hematoencefálica/metabolismo , Hipotálamo/metabolismo , Ratones , Neuronas/metabolismo
10.
Brain Res ; 1627: 90-100, 2015 Nov 19.
Artículo en Inglés | MEDLINE | ID: mdl-26410779

RESUMEN

Blood Brain Barrier (BBB) exposed to realistic concentrations (comparable to a chronic heavy smoker) of Cigarette Smoke Extract (CSE) triggers a strong endothelial inflammatory response which can lead to the onset of neurological disorders. The involvement of Reactive Oxygen Species (ROS) in this inflammatory cascade is evident from the up-regulation of nuclear factor erythroid 2 related factor 2 (Nrf-2), a transcription factor involved in anti-oxidant response signaling in CSE exposed endothelial cells. We have shown that pre-treatment with α-tocopherol and/or ascorbic acid is highly protective for the BBB, thus suggesting that, prophylactic administration of antioxidants can reduce CSE and/or inflammatory-dependent BBB damage. We have assessed and ranked the protective effects of 5 popular OTC antioxidants (Coenzyme Q10, melatonin, glutathione, lipoic acid and resveratrol) against CSE-induced BBB endothelial damage using hCMEC/D3 cells. The analysis of pro-inflammatory cytokines release by ELISA revealed that resveratrol, lipoic acid melatonin and Co-Q10 inhibited the BBB endothelial release of pro-inflammatory cytokines IL-6 and IL-8, reduced (not Co-Q10) CSE-induced up-regulation of Platelet Cell Adhesion Molecule-1 (PECAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1) & E-selectin and inhibited monocytes-endothelial cell adhesion. The anti-inflammatory effects correlated with the anti-oxidative protection endowed by these compounds as evidenced by upregulation of NADPH: Quinone Oxidoreductase 1 (NQO1) and reduced cellular oxidative stress. CSE-induced release of Vascular Endothelial Growth Factor (VEGF) was inhibited by all tested compounds although the effect was not strictly dose-dependent. Further in vivo studies are required to validate our results and expand our current study to include combinatorial treatments.


Asunto(s)
Antioxidantes/farmacología , Barrera Hematoencefálica/citología , Endotelio/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/química , Productos de Tabaco , Línea Celular Transformada , Supervivencia Celular/efectos de los fármacos , Proteínas Cullin/metabolismo , Citocinas/metabolismo , Ensayo de Inmunoadsorción Enzimática , Glutatión/metabolismo , Humanos , L-Lactato Deshidrogenasa/metabolismo , Melatonina/farmacología , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/metabolismo , Resveratrol , Estilbenos/farmacología , Ubiquinona/análogos & derivados , Ubiquinona/farmacología , Regulación hacia Arriba/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular/metabolismo
11.
Expert Opin Drug Discov ; 10(2): 141-55, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25388782

RESUMEN

INTRODUCTION: The majority of therapeutics, small molecule or biologics, developed for the CNS do not penetrate the blood-brain barrier (BBB) sufficiently to induce pharmacologically meaningful effects on CNS targets. To improve the efficiency of CNS drug discovery, several in vitro models of the BBB have been used to aid early selection of molecules with CNS exposure potential. However, correlative studies suggest relatively poor predictability of in vitro BBB models underscoring the need to combine in vitro and in vivo BBB penetration assessment into an integrated preclinical workflow. AREAS COVERED: This review gives a brief general overview of in vitro and in vivo BBB models used in the pre-clinical evaluation of CNS-targeting drugs, with particular focus on the recent progress in developing humanized models. The authors discuss the advantages, limitations, in vitro-in vivo correlation, and integration of these models into CNS drug discovery and development with the aim of improving translation. EXPERT OPINION: Often, a simplistic rationalization of the CNS drug discovery and development process overlooks or even ignores the need for an early and predictive assessment of the BBB permeability. Indeed, past failures of CNS candidates in clinical trials argue strongly that the early deployment of in vitro and in vivo models for assessing BBB permeability, mechanisms of transport and brain exposure of leads, and the co-development of BBB delivery strategies will improve translation and increase the clinical success of CNS pipelines.


Asunto(s)
Anticuerpos Monoclonales/farmacocinética , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/metabolismo , Descubrimiento de Drogas/métodos , Modelos Biológicos , Animales , Anticuerpos Monoclonales/farmacología , Barrera Hematoencefálica/citología , Encéfalo/citología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Evaluación Preclínica de Medicamentos , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Humanos , Especificidad de la Especie
12.
Biol Aujourdhui ; 208(3): 225-35, 2014.
Artículo en Francés | MEDLINE | ID: mdl-25474004

RESUMEN

Information exchanges between the brain and the periphery are key stages in the regulation of various physiological functions. The mediobasal hypothalamus, which ensures a large part of these functions, must be permanently informed about the physiological state of the body to guarantee the maintaining of homeostasis. For that purpose, it possesses a peculiar blood-brain interface due to the presence of specialized glial cells called tanycytes. This review describes the organization of the blood-hypothalamus interface and characterizes the peculiar place of tanycytes within it, as well as their striking capacity to remodel their own interface in order to ensure the regulation of various physiological functions.


Asunto(s)
Barrera Hematoencefálica/citología , Células Ependimogliales/fisiología , Hipotálamo/citología , Animales , Barrera Hematoencefálica/anatomía & histología , Barrera Hematoencefálica/fisiología , Metabolismo Energético/fisiología , Homeostasis/fisiología , Humanos , Hipotálamo/anatomía & histología , Hipotálamo/metabolismo , Plasticidad Neuronal , Reproducción/fisiología
13.
PLoS One ; 9(11): e113126, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25426944

RESUMEN

Alzheimer's disease (AD) is the most common form of senile dementia which is characterized by abnormal amyloid beta (Aß) accumulation and deposition in brain parenchyma and cerebral capillaries, and leads to blood-brain barrier (BBB) disruption. Despite great progress in understanding the etiology of AD, the underlying pathogenic mechanism of BBB damage is still unclear, and no effective treatment has been devised. The standard Ginkgo biloba extract EGb761 has been widely used as a potential cognitive enhancer for the treatment of AD. However, the cellular mechanism underlying the effect remain to be clarified. In this study, we employed an immortalized endothelial cell line (bEnd.3) and incubation of Aß(1-42) oligomer, to mimic a monolayer BBB model under conditions found in the AD brain. We investigated the effect of EGb761 on BBB and found that Aß1-42 oligomer-induced cell injury, apoptosis, and generation of intracellular reactive oxygen species (ROS), were attenuated by treatment with EGb761. Moreover, treatment of the cells with EGb761 decreased BBB permeability and increased tight junction scaffold protein levels including ZO-1, Claudin-5 and Occludin. We also found that the Aß(1-42) oligomer-induced upregulation of the receptor for advanced glycation end-products (RAGE), which mediates Aß cytotoxicity and plays an essential role in AD progression, was significantly decreased by treatment with EGb761. To our knowledge, we provide the first direct in vitro evidence of an effect of EGb761 on the brain endothelium exposed to Aß(1-42) oligomer, and on the expression of tight junction (TJ) scaffold proteins and RAGE. Our results provide a new insight into a possible mechanism of action of EGb761. This study provides a rational basis for the therapeutic application of EGb761 in the treatment of AD.


Asunto(s)
Péptidos beta-Amiloides/antagonistas & inhibidores , Células Endoteliales/metabolismo , Nootrópicos/farmacología , Fragmentos de Péptidos/antagonistas & inhibidores , Extractos Vegetales/farmacología , Especies Reactivas de Oxígeno/antagonistas & inhibidores , Péptidos beta-Amiloides/farmacología , Apoptosis/efectos de los fármacos , Barrera Hematoencefálica/citología , Barrera Hematoencefálica/efectos de los fármacos , Línea Celular Transformada , Claudina-5/genética , Claudina-5/metabolismo , Células Endoteliales/citología , Expresión Génica/efectos de los fármacos , Ginkgo biloba , Humanos , Modelos Biológicos , Ocludina/genética , Ocludina/metabolismo , Fragmentos de Péptidos/farmacología , Especies Reactivas de Oxígeno/agonistas , Especies Reactivas de Oxígeno/metabolismo , Receptor para Productos Finales de Glicación Avanzada , Receptores Inmunológicos/genética , Receptores Inmunológicos/metabolismo , Uniones Estrechas/efectos de los fármacos , Proteína de la Zonula Occludens-1/genética , Proteína de la Zonula Occludens-1/metabolismo
14.
PLoS One ; 9(3): e90221, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24621608

RESUMEN

This study investigated the histological tissue reaction to long-term implanted cerebral open flow microperfusion (cOFM) probes in the frontal lobe of the rat brain. Most probe-based cerebral fluid sampling techniques are limited in application time due to the formation of a glial scar that hinders substance exchange between brain tissue and the probe. A glial scar not only functions as a diffusion barrier but also alters metabolism and signaling in extracellular brain fluid. cOFM is a recently developed probe-based technique to continuously sample extracellular brain fluid with an intact blood-brain barrier. After probe implantation, a 2 week healing period is needed for blood-brain barrier reestablishment. Therefore, cOFM probes need to stay in place and functional for at least 15 days after implantation to ensure functionality. Probe design and probe materials are optimized to evoke minimal tissue reaction even after a long implantation period. Qualitative and quantitative histological tissue analysis revealed no continuous glial scar formation around the cOFM probe 30 days after implantation and only a minor tissue reaction regardless of perfusion of the probe.


Asunto(s)
Encéfalo/citología , Electrodos Implantados/efectos adversos , Perfusión/instrumentación , Animales , Barrera Hematoencefálica/citología , Barrera Hematoencefálica/metabolismo , Encéfalo/metabolismo , Proteínas de Unión al Calcio/metabolismo , Lóbulo Frontal/citología , Lóbulo Frontal/metabolismo , Proteína Ácida Fibrilar de la Glía , Masculino , Proteínas de Microfilamentos/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Diseño de Prótesis , Ratas , Ratas Sprague-Dawley , Factores de Tiempo
15.
PLoS One ; 8(11): e78464, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24223811

RESUMEN

Renovascular hypertension induced by 2 Kidney-1 Clip (2K-1C) is a renin-angiotensin-system (RAS)-dependent model, leading to renal vascular rarefaction and renal failure. RAS inhibitors are not able to reduce arterial pressure (AP) and/or preserve the renal function, and thus, alternative therapies are needed. Three weeks after left renal artery occlusion, fluorescently tagged mesenchymal stem cells (MSC) (2×10(5) cells/animal) were injected weekly into the tail vein in 2K-1C hypertensive rats. Flow cytometry showed labeled MSC in the cortex and medulla of the clipped kidney. MSC prevented a further increase in the AP, significantly reduced proteinuria and decreased sympathetic hyperactivity in 2K-1C rats. Renal function parameters were unchanged, except for an increase in urinary volume observed in 2K-1C rats, which was not corrected by MSC. The treatment improved the morphology and decreased the fibrotic areas in the clipped kidney and also significantly reduced renal vascular rarefaction typical of 2K-1C model. Expression levels of IL-1ß, TNF-α angiotensinogen, ACE, and Ang II receptor AT1 were elevated, whereas AT2 levels were decreased in the medulla of the clipped kidney. MSC normalized these expression levels. In conclusion, MSC therapy in the 2K-1C model (i) prevented the progressive increase of AP, (ii) improved renal morphology and microvascular rarefaction, (iii) reduced fibrosis, proteinuria and inflammatory cytokines, (iv) suppressed the intrarenal RAS, iv) decreased sympathetic hyperactivity in anesthetized animals and v) MSC were detected at the CNS suggesting that the cells crossed the blood-brain barrier. This therapy may be a promising strategy to treat renovascular hypertension and its renal consequences in the near future.


Asunto(s)
Hipertensión Renovascular/terapia , Trasplante de Células Madre Mesenquimatosas , Proteinuria/terapia , Animales , Presión Sanguínea , Barrera Hematoencefálica/citología , Barrera Hematoencefálica/metabolismo , Colorantes Fluorescentes , Expresión Génica , Hipertensión Renovascular/genética , Hipertensión Renovascular/metabolismo , Hipertensión Renovascular/patología , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Riñón/metabolismo , Riñón/patología , Masculino , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/fisiología , Peptidil-Dipeptidasa A/genética , Peptidil-Dipeptidasa A/metabolismo , Proteinuria/genética , Proteinuria/metabolismo , Proteinuria/patología , Ratas , Ratas Wistar , Receptor de Angiotensina Tipo 1/genética , Receptor de Angiotensina Tipo 1/metabolismo , Receptor de Angiotensina Tipo 2/genética , Receptor de Angiotensina Tipo 2/metabolismo , Arteria Renal/cirugía , Sistema Renina-Angiotensina/genética , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo
16.
Biol Pharm Bull ; 34(8): 1246-51, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21804213

RESUMEN

Furanocoumarin derivatives, known as components of grapefruit juice, showing inhibitory effects against P-glycoprotein (P-gp) in the intestine are also contained in the plants of rutaceae and umbelliferae families, which are used as components of Kampo extract medicines. In this study, we investigated the inhibitory effects of byakangelicol and rivulobirin A, known as furanocoumarins showing P-gp inhibitory effect using Caco-2 monolayer, against P-gp at the blood-brain barrier (BBB) under both in vitro and in vivo conditions. First we studied the membrane permeability of furanocoumarins to clarify whether they can be absorbed from the intestine. Both furanocoumarins showed high permeability through the Caco-2 monolayer, suggesting that they can easily reach the systemic circulation after oral administration. Then, we evaluated the effect of these furanocoumarins on the uptake of calcein acetoxymethyl ester (calcein-AM), a P-gp substrate, into bovine brain microvascular endothelial cells (BBMEC). Both furanocoumarins significantly increased the uptake amount of calcein-AM into BBMEC by the inhibition of P-gp at the BBB in vitro. Next we also investigated the P-gp inhibitory effect of these furanocoumarins at the rat BBB in vivo using verapamil as a P-gp substrate. Both furanocoumarins increased the B/P ratio of verapamil compared to the control, even under in vivo conditions; however, the extent of the inhibitory effect was much lower than in vitro condition. In conclusion, byakangelicol and rivulobirin A may inhibit P-gp expressed at the BBB even under in vivo conditions. Further studies using Kampo extract medicines under in vivo condition are necessary for safe drug therapy.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Barrera Hematoencefálica/efectos de los fármacos , Cumarinas/farmacología , Inhibidores Enzimáticos/farmacología , Furanos/farmacología , Furocumarinas/farmacología , Interacciones de Hierba-Droga , Extractos Vegetales/farmacología , Animales , Apiaceae/química , Transporte Biológico/efectos de los fármacos , Barrera Hematoencefálica/citología , Barrera Hematoencefálica/metabolismo , Células CACO-2 , Bovinos , Citrus paradisi/química , Cumarinas/farmacocinética , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Inhibidores Enzimáticos/farmacocinética , Fluoresceínas/metabolismo , Furanos/farmacocinética , Furocumarinas/farmacocinética , Humanos , Absorción Intestinal , Masculino , Medicina Kampo , Permeabilidad , Extractos Vegetales/química , Extractos Vegetales/farmacocinética , Ratas , Ratas Wistar , Rutaceae/química , Verapamilo/metabolismo
17.
J Comp Neurol ; 518(7): 943-62, 2010 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-20127760

RESUMEN

The median eminence is one of the seven so-called circumventricular organs. It is located in the basal hypothalamus, ventral to the third ventricle and adjacent to the arcuate nucleus. This structure characteristically contains a rich capillary plexus and features a fenestrated endothelium, making it a direct target of blood-borne molecules. The median eminence also contains highly specialized ependymal cells called tanycytes, which line the floor of the third ventricle. It has been hypothesized that one of the functions of these cells is to create a barrier that prevents substances in the portal capillary spaces from entering the brain. In this paper, we utilize immunohistochemistry to study the expression of tight junction proteins in the cells that compose the median eminence in adult mice. Our results indicate that tanycytes of the median eminence express occludin, ZO-1, and claudin 1 and 5, but not claudin 3. Remarkably, these molecules are organized as a continuous belt around the cell bodies of the tanycytes that line the ventral part of the third ventricle. In contrast, the tanycytes at the periphery of the arcuate nucleus do not express claudin 1 and instead exhibit a disorganized expression pattern of occludin, ZO-1, and claudin 5. Consistent with these observations, permeability studies using peripheral or central injections of Evans blue dye show that only the tanycytes of the median eminence are joined at their apices by functional tight junctions, whereas tanycytes located at the level of the arcuate nucleus form a permeable layer. In conclusion, this study reveals a unique expression pattern of tight junction proteins in hypothalamic tanycytes, which yields new insights into their barrier properties.


Asunto(s)
Barrera Hematoencefálica/citología , Barrera Hematoencefálica/metabolismo , Hipotálamo/citología , Hipotálamo/metabolismo , Eminencia Media/metabolismo , Proteínas de la Membrana/metabolismo , Uniones Estrechas/metabolismo , Animales , Claudina-1 , Claudina-5 , Inmunohistoquímica , Masculino , Eminencia Media/citología , Ratones , Ratones Endogámicos C57BL , Ocludina , Fosfoproteínas/metabolismo , Proteína de la Zonula Occludens-1
18.
Neurosci Lett ; 446(2-3): 59-64, 2008 Dec 03.
Artículo en Inglés | MEDLINE | ID: mdl-18817843

RESUMEN

Up to now no standard cell culture model of the blood-brain barrier is available. However, several models based on primary cells or continuous cell lines have been characterized and described in respect of different applications. One of the most important characteristics of the blood-brain barrier is the restriction of paracellular transport, respectively its tightness. Human cell line ECV304 is one of the promising continuous cell lines for blood-brain barrier modelling due to two reasons: on the one hand the cells are able to form significant tighter layers than most of the other cell lines used and on the other hand several properties of the blood-brain barrier are inducible by using glioma-conditioned medium. Claudins are transmembranal proteins which form the backbone of the tight junctions at the blood-brain barrier. We have investigated the presence and inducibility of the expression of Claudin-1, Claudin-3 and Claudin-5 using immunofluorescence microscopy. For the first time this study proves the presence of Claudin-1, Claudin-3 and Claudin-5 in ECV304 (obtained from ECACC) cell layers and the inducibility of their expression by glioma-conditioned media.


Asunto(s)
Barrera Hematoencefálica/citología , Barrera Hematoencefálica/metabolismo , Línea Celular , Células Endoteliales/metabolismo , Proteínas de la Membrana/metabolismo , Animales , Barrera Hematoencefálica/efectos de los fármacos , Neoplasias Encefálicas/metabolismo , Claudina-1 , Claudina-3 , Claudina-5 , Medios de Cultivo Condicionados/farmacología , Evaluación Preclínica de Medicamentos/métodos , Células Endoteliales/efectos de los fármacos , Técnica del Anticuerpo Fluorescente , Glioma/metabolismo , Humanos , Transporte de Proteínas/fisiología , Ratas , Uniones Estrechas/metabolismo
19.
Artículo en Inglés | MEDLINE | ID: mdl-18042368

RESUMEN

We have previously shown that glucose utilization and glucose transport were impaired in the brain of rats made deficient in n-3 polyunsaturated fatty acids (PUFA). The present study examines whether n-3 PUFA affect the expression of glucose transporter GLUT1 and glucose transport activity in the endothelial cells of the blood-brain barrier. GLUT1 expression in the cerebral cortex microvessels of rats fed different amounts of n-3 PUFA (low vs. adequate vs. high) was studied. In parallel, the glucose uptake was measured in primary cultures of rat brain endothelial cells (RBEC) exposed to supplemental long chain n-3 PUFA, docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids, or to arachidonic acid (AA). Western immunoblotting analysis showed that endothelial GLUT1 significantly decreased (-23%) in the n-3 PUFA-deficient microvessels compared to control ones, whereas it increased (+35%) in the microvessels of rats fed the high n-3 PUFA diet. In addition, binding of cytochalasin B indicated that the maximum binding to GLUT1 (Bmax) was reduced in deficient rats. Incubation of RBEC with 15 microM DHA induced the membrane DHA to increase at a level approaching that of cerebral microvessels isolated from rats fed the high n-3 diet. Supplementation of RBEC with DHA or EPA increased the [(3)H]-3-O-methylglucose uptake (reflecting the basal glucose transport) by 35% and 50%, respectively, while AA had no effect. In conclusion, we suggest that n-3 PUFA can modulate the brain glucose transport in endothelial cells of the blood-brain barrier, possibly via changes in GLUT1 protein expression and activity.


Asunto(s)
Barrera Hematoencefálica/efectos de los fármacos , Células Endoteliales/efectos de los fármacos , Ácidos Grasos Omega-3/farmacología , Glucosa/metabolismo , Animales , Transporte Biológico/efectos de los fármacos , Barrera Hematoencefálica/citología , Barrera Hematoencefálica/metabolismo , Western Blotting , Células Cultivadas , Ácidos Docosahexaenoicos/farmacología , Relación Dosis-Respuesta a Droga , Ácido Eicosapentaenoico/farmacología , Células Endoteliales/citología , Células Endoteliales/metabolismo , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-3/metabolismo , Ácidos Grasos Omega-6/metabolismo , Femenino , Glucosa/farmacocinética , Transportador de Glucosa de Tipo 1/metabolismo , Fosfatidiletanolaminas/metabolismo , Embarazo , Ratas
20.
Brain Res ; 1171: 18-29, 2007 Sep 26.
Artículo en Inglés | MEDLINE | ID: mdl-17764664

RESUMEN

Mast cells, derived from the hematopoietic stem cell, are present in the brain from birth. During development, mast cells occur in two locations, namely the pia and the brain parenchyma. The current hypothesis regarding their origin states that brain mast cells (or their precursors) enter the pia and access the thalamus by traveling along the abluminal wall of penetrating blood vessels. The population in the pia reaches a maximum at postnatal (PN) day 11, and declines rapidly thereafter. Chromatin fragmentation suggests that this cell loss is due to apoptosis. In contrast, the thalamic population expands from PN8 to reach adult levels at PN30. Stereological analysis demonstrates that mast cells home to blood vessels. More than 96% of mast cells are inside the blood-brain barrier, with ~90% contacting the blood vessel wall or its extracellular matrix. Mast cells express alpha4 integrins -- a potential mechanism for adhesion to the vascular wall. Despite the steady increase in the volume of microvasculature, at all ages studied, mast cells are preferentially located on large diameter vessels (>16 microm; possibly arteries), and contact only those maturing blood vessels that are ensheathed by astroglial processes. Mast cells not only home to large vessels but also maintain a preferential position at branch points, sites of vessel growth. This observation presents the possibility that mast cells participate in and/or regulate vasculature growth or differentiation. The biochemical and molecular signals that induce mast cell homing in the CNS is an area of active investigation.


Asunto(s)
Barrera Hematoencefálica/citología , Barrera Hematoencefálica/crecimiento & desarrollo , Encéfalo/citología , Encéfalo/fisiología , Mastocitos/fisiología , Factores de Edad , Análisis de Varianza , Animales , Animales Recién Nacidos , Apoptosis/fisiología , Avidina/metabolismo , Vasos Sanguíneos/citología , Vasos Sanguíneos/crecimiento & desarrollo , Movimiento Celular/fisiología , Proliferación Celular , Femenino , Regulación del Desarrollo de la Expresión Génica/fisiología , Laminina/metabolismo , Masculino , Proteínas del Tejido Nervioso/metabolismo , Piamadre/citología , Piamadre/fisiología , Ratas , Ratas Long-Evans , Tálamo/citología , Tálamo/crecimiento & desarrollo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA